Holen Sie sich die Stockscreener-App
16.53
1.90%
-0.32
Vorhandelsmarkt:
17.03
0.50
+3.02%
Schlusskurs vom Vortag:
$16.85
Offen:
$16.9
24-Stunden-Volumen:
72,824
Relative Volume:
0.67
Marktkapitalisierung:
$95.21M
Einnahmen:
$100.44M
Nettoeinkommen (Verlust:
$-133.16M
KGV:
-0.6417
EPS:
-25.76
Netto-Cashflow:
$-94.85M
1W Leistung:
+16.74%
1M Leistung:
+28.94%
6M Leistung:
+104.07%
1J Leistung:
+13.63%
1-Tages-Spanne:
$15.50
$17.01
1-Wochen-Bereich:
$14.49
$18.70
52-Wochen-Spanne:
$6.50
$39.50
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Firmenname
Atara Biotherapeutics Inc
Sektor
Branche
Telefon
805-623-4244
Adresse
2380 CONEJO SPECTRUM ST, THOUSAND OAKS, CA
Vergleichen Sie ATRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
16.53 | 95.21M | 100.44M | -133.16M | -94.85M | -25.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.11 | 106.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.59 | 80.61B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
649.26 | 38.82B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.55 | 31.03B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.15 | 29.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-09 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-11-09 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-07-20 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-07-13 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-07-13 | Herabstufung | Stifel | Buy → Hold |
| 2022-05-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-05-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-12-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-30 | Eingeleitet | Evercore ISI | Outperform |
| 2020-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-23 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-09-27 | Herabstufung | Goldman | Neutral → Sell |
| 2019-09-16 | Herabstufung | Jefferies | Buy → Hold |
| 2019-06-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2019-05-30 | Eingeleitet | ROTH Capital | Buy |
| 2019-05-23 | Eingeleitet | Stifel | Buy |
| 2019-01-23 | Eingeleitet | Mizuho | Buy |
| 2018-04-10 | Eingeleitet | JP Morgan | Overweight |
| 2018-03-16 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-05 | Bestätigt | Jefferies | Buy |
| 2018-02-28 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-01-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Atara Biotherapeutics Inc Aktie (ATRA) Neueste Nachrichten
Where are the Opportunities in (ATRA) - Stock Traders Daily
Here's Why You Should Consider Buying Atara Biotherapeutics Stock - Barchart
Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) high institutional ownership speaks for itself as stock continues to impress, up 27% over last week - Yahoo Finance
Is Atara Biotherapeutics (NASDAQ:ATRA) In A Good Position To Deliver On Growth Plans? - Simply Wall St
Analysts Set Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Target Price at $18.75 - MarketBeat
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Holdings Increased by State Street Corp - Defense World
Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's Why - Yahoo Finance
Biotech Stocks Facing FDA Decision In January 2025 - Nasdaq
(ATRA) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Atara Biotherapeutics Amends and Restates Bylaws in Recent Board Decision - Defense World
Atara Biotherapeutics (NASDAQ:ATRA) Research Coverage Started at Rodman & Renshaw - Defense World
Atara Biotherapeutics Announces FDA Clearance of IND for ATA2271, a Next-Generation Autologous Mesothelin-Targeted CAR T with Novel PD1DNR and 1XX Technologies Combined to Treat Solid Tumors - Marketscreener.com
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares Bought by Fmr LLC - Defense World
Atara Biotherapeutics (NASDAQ:ATRA) Raised to “Strong-Buy” at RODMAN&RENSHAW - Defense World
RODMAN&RENSHAW Upgrades Atara Biotherapeutics (NASDAQ:ATRA) to "Strong-Buy" - MarketBeat
Rodman & Renshaw bullish on Atara stock, sees upside in CAR-T autoimmune therapies - Investing.com Canada
Rodman & Renshaw Initiates Coverage of Atara Biotherapeutics (ATRA) with Buy Recommendation - MSN
Atara Biotherapeutics (NASDAQ:ATRA) Coverage Initiated at Rodman & Renshaw - MarketBeat
When (ATRA) Moves Investors should Listen - Stock Traders Daily
Head to Head Contrast: Atara Biotherapeutics (NASDAQ:ATRA) versus Fresh Tracks Therapeutics (NASDAQ:FRTX) - Defense World
Rajani DinavahiChief Medical Officer | Atara Biotherapeutics - Los Angeles Times
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives $16.67 Consensus PT from Analysts - MarketBeat
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares Sold by Centiva Capital LP - MarketBeat
(ATRA) Investment Report - Stock Traders Daily
Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference - Business Wire
Atara Biotherapeutics CEO sells shares worth $18,633 By Investing.com - Investing.com South Africa
Atara biotherapeutics CFO Eric Hyllengren sells $15,274 in stock By Investing.com - Investing.com Nigeria
Atara biotherapeutics EVP sells $11,198 in stock By Investing.com - Investing.com Australia
Atara biotherapeutics CFO Eric Hyllengren sells $15,274 in stock - Investing.com India
Atara biotherapeutics EVP sells $11,198 in stock - Investing.com India
Atara Biotherapeutics CEO sells shares worth $18,633 - Investing.com
FUJIFILM Diosynth Biotechnologies Celebrates the Expansion Completion at its California Cell Therapy Facility - GlobeNewswire Inc.
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
How the (ATRA) price action is used to our Advantage - Stock Traders Daily
EcoR1 Capital, LLC Increases Stake in Atara Biotherapeutics Inc - GuruFocus.com
Atara Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Atara Biotherapeutics Reports Q3 2024 Financial Progress - TipRanks
Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference - Business Wire
Atara Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Stifel raises Atara Bio shares target, keeps hold rating ahead of clinical data - Investing.com UK
Atara Biotherapeutics (NASDAQ:ATRA) Price Target Raised to $21.00 - MarketBeat
Atara Biotherapeutics: Q3 Earnings Snapshot - Houston Chronicle
Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings Flash (ATRA) ATARA BIOTHERAPEUTICS Reports Q3 Revenue $40.2M - Marketscreener.com
Atara Bio Q3 Revenue Soars 1,814% to $40.2M, FDA Decision Looms for Tab-cel Drug | ATRA Stock News - StockTitan
Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress - Business Wire
(ATRA) On The My Stocks Page - Stock Traders Daily
Atara Biotherapeutics (ATRA) to Release Quarterly Earnings on Tuesday - MarketBeat
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement - Simply Wall St
Finanzdaten der Atara Biotherapeutics Inc-Aktie (ATRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.08%
0.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):